Success Metrics

Clinical Success Rate
93.3%

Based on 14 completed trials

Completion Rate
93%(14/15)
Active Trials
0(0%)
Results Posted
29%(4 trials)
Terminated
1(6%)

Phase Distribution

Ph phase_4
1
6%
Ph phase_2
6
38%
Ph phase_1
1
6%
Ph phase_3
8
50%

Phase Distribution

1

Early Stage

6

Mid Stage

9

Late Stage

Phase Distribution16 total trials
Phase 1Safety & dosage
1(6.3%)
Phase 2Efficacy & side effects
6(37.5%)
Phase 3Large-scale testing
8(50.0%)
Phase 4Post-market surveillance
1(6.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

87.5%

14 of 16 finished

Non-Completion Rate

12.5%

2 ended early

Currently Active

0

trials recruiting

Total Trials

16

all time

Status Distribution
Completed(14)
Terminated(2)

Detailed Status

Completed14
Withdrawn1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
0
Success Rate
93.3%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (6.3%)
Phase 26 (37.5%)
Phase 38 (50.0%)
Phase 41 (6.3%)

Trials by Status

withdrawn16%
completed1488%
terminated16%

Recent Activity

Clinical Trials (16)

Showing 16 of 16 trials
NCT01585298Phase 4

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Completed
NCT00333138Phase 2

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis

Completed
NCT00239785Phase 3

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

Completed
NCT00731692Phase 3

This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS.

Terminated
NCT00099801Phase 3

Safety and Efficacy of FTY720 in Adult Patients Who Receive a Kidney Transplant

Completed
NCT01791192Phase 2

Study of FTY720 in Patients With Uveitis

Withdrawn
NCT00239863Phase 3

Efficacy and Safety of FTY720 Versus Mycophenolate Mofetil (MMF, Roche Brand) in de Novo Adult Renal Transplant Recipients

Completed
NCT00239798Phase 2

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

Completed
NCT01127750Phase 3

Tolerability and Safety and Health Outcomes in Relapsing Multiple Sclerosis (MS) Patients

Completed
NCT00098735Phase 3

Efficacy and Safety of FTY720 in Patients Who Receive a Kidney Transplantation

Completed
NCT00785083Phase 2

A Study of the Effect of FTY720 on Pulmonary Function in Patients With Moderate Asthma

Completed
NCT00239902Phase 2

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

Completed
NCT00239876Phase 3

Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

Completed
NCT00239811Phase 3

Long Term Efficacy and Safety of FTY720 in de Novo Adult Renal Transplant Recipients

Completed
NCT00537082Phase 2

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)

Completed
NCT00416845Phase 1

Effects of FTY720 on Heart and Lung Functions in Healthy Volunteers

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16